HIV-1 drug resistance mutations: Potential applications for point-of-care Genotypic resistance testing

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Rhee, Soo Yon ^a   Jordan, Michael R ^b   Raizes, Elliot ^c   Chua, Arlene ^d,e   Parkin, Neil ^f   Kantor, Rami ^g   Van Zy, Gert U ^h,i   Mukui, Irene ^j   Hosseinipour, Mina C ^k   Frenkel, Lisa M ^l   Ndembi, Nicaise ^m   Hamers, Raph L ⁿ   De Wit, Tobias F Rinke ⁿ   Wallis, Carole L ^o   Gupta, Ravindra K ^p   Fokam, Joseph ^q,r   Zeh, Clement ^c   Schapiro, Jonathan M ^s   Carmona, Sergio ^h,t   Katzenstein, David ^a   Tang, Michele ^a   Aghokeng, Avelin F ^u   De Oliveira, Tulio ^v   Wensing, Annemarie M J ^w   Gallant, Joel E ^x   Wainberg, Mark A ^y   Richman, Douglas D ^z,aa   Fitzgibbon, Joseph E ^ab   Schito, Marco ^ac   Bertagnolio, Silvia ^ad   Yang, Chunfu ^c   Shafer, Robert W ^a   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e TAN TOCK SENG HOSPITAL   (Singapore)

^f DATA FIRST CONSULTING INC   (United States)

^g BROWN UNIVERSITY   (United States)

^h NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

ⁱ STELLENBOSCH UNIVERSITY   (South Africa)

^j MINISTRY OF HEALTH   (Kenya)

^k UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^l UNIVERSITY OF WASHINGTON   (United States)

^m INSTITUTE OF HUMAN VIROLOGY NIGERIA   (Nigeria)

ⁿ UNIVERSITY OF AMSTERDAM   (Netherlands)

^o LANCET LABORATORIES   (South Africa)

^p UNIVERSITY COLLEGE LONDON   (United Kingdom)

^q Laboratory of Systems Biology   (Cameroon)

^r UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^s National Hemophilia Center   (Israel)

^t UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^u Institute of Medical Research and Medicinal Plant Studies Yaounde   (Cameroon)

^v UNIVERSITY OF KWAZULU NATAL   (South Africa)

^w UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^x Southwest CARE Center   (United States)

^y MCGILL UNIVERSITY   (Canada)

^z UNIVERSITY OF CALIFORNIA   (United States)

^aa VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^ab NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^ac HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^ad WORLD HEALTH ORGANIZATION   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ATAZANAVIR; DARUNAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ALLELE; ANTIVIRAL RESISTANCE; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISEASE TRANSMISSION; GENOTYPE; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; POINT MUTATION; POINT OF CARE TESTING; PREVALENCE; SEQUENCE ANALYSIS; TREATMENT INDICATION; VIRUS LOAD; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPING TECHNIQUE; HIV INFECTIONS; MUTATION; POINT OF CARE SYSTEM; PROCEDURES; TREATMENT FAILURE;

ATAZANAVIR SULFATE; DARUNAVIR; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; LOPINAVIR; MUTATION; POINT-OF-CARE SYSTEMS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT FAILURE;

EID: 84956902464     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145772     Document Type: Article

References (60)

1. Chi BH, Bolton-Moore C, Holmes CB. Prevention of mother-to-child HIV transmission within the continuum of maternal, newborn, and child health services. Curr Opin HIV AIDS. 2013;8(5):498-503. Epub 2013/07/23. doi: 10.1097/COH.0b013e3283637f7a PMID: 23872611.
2. Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7):e1001245. Epub 2012/07/18. doi: 10. 1371/journal.pmed.1001245 PMID: 22802730; PubMed Central PMCID: PMC3393664.
3. Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339(6122):961-5. Epub 2013/02/23. doi: 10. 1126/science.1230413 PMID: 23430655; PubMed Central PMCID: PMC3860268.
4. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966-71. Epub 2013/02/23. doi: 10.1126/science.1228160 PMID: 23430656.
5. Holmes CB, CogginW, Jamieson D, Mihm H, Granich R, Savio P, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA. 2010;304(3):313-20. Epub 2010/07/20. doi: 10.1001/jama.2010.993 PMID: 20639565.
6. HIV/AIDS Programme World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013.
7. HIV/AIDS Programme World Health Organization. WHO HIV Drug Resistance Report 2012. 2012.
8. Bertagnolio S, Perno CF, Vella S, Pillay D. The Impact of HIV Drug Resistance on the Selection of Firstand Second-Line ART in Resource-Limited Settings. J Infect Dis. 2013;207 Suppl 2:S45-8. doi: 10. 1093/infdis/jit121 PMID: 23687288.
9. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):155-66. Epub 2010/02/27. doi: 10.1016/S1473-3099 (09) 70328-7 PMID: 20185094.
10. McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ. 2013;91(5):377-85E. Epub 2013/05/17. doi: 10.2471/BLT.12.112946 PMID: 23678201; PubMed Central PMCID: PMC3646348.
11. Aghokeng AF, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, et al. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis. 2014;58(1):99-109. doi: 10.1093/cid/cit627 PMID: 24076968.
12. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013;18(1):115-23. Epub 2012/10/12. doi: 10.3851/IMP2437 PMID: 23052978.
13. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9(7):409-17. doi: 10.1016/S1473-3099 (09) 70136-7 PMID: 19555900.
14. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 2012;14(1):17-27. Epub 2012/02/03. PMID: 22297501.
15. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380(9849):1250-8. Epub 2012/07/26. doi: 10.1016/S0140-6736 (12) 61038-1 PMID: 22828485.
16. Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual patient and sequence-level meta-analysis. PLoS Med. 2015; (In press).
17. Hamers RL, Siwale M, Wallis CL, Labib M, van Hasselt R, Stevens WS, et al. HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2010;55(1):95-101. Epub 2010/06/30. doi: 10.1097/QAI. 0b013e3181e544e0 PMID: 20585262.
18. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 drug resistance in antiretroviralnaive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11(10):750-9. Epub 2011/08/02. doi: 10.1016/S1473-3099 (11) 70149-9 PMID: 21802367.
19. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, et al. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2014;22(3):642-50. PMID: 25101529.
20. Van Zyl GU, Liu TF, Claassen M, Engelbrecht S, de Oliveira T, Preiser W, et al. Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens. PLoS One. 2013;8(6):e67188. doi: 10.1371/journal. pone.0067188 PMID: 23840622.
21. Rivadeneira E, Devos J, Dzioban E, Ngeno B, Zhang G, Sebatier J, et al. High prevalence of L74V/I mutations in Kenyan children with virological failure (abstract 52). International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge, June 3-7, 2014, Berlin, Germany. 2014.
22. Malan DR, Krantz E, David N, Rong Y, Mathew M, Iloeje UH, et al. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic). 2010;9(1):34-42. doi: 10.1177/1545109709355828 PMID: 20071596.
23. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviralnaive patients. J Acquir Immune Defic Syndr. 2008;47(2):161-7. doi: 10.1097/QAI. 0b013e31815ace6a PMID: 17971713.
24. Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, et al. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis. 2012;206(12):1920-30. doi: 10.1093/infdis/jis613 PMID: 23148287; PubMed Central PMCID: PMC3502379.
25. Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, et al. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010;54(10):4253-61. Epub 2010/07/28. doi: 10.1128/AAC.00574-10 PMID: 20660676; PubMed Central PMCID: PMC2944562.
26. Weinheimer S, Discotto L, Friborg J, Yang H, Colonno R. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob Agents Chemother. 2005;49(9):3816-24. doi: 10.1128/AAC.49.9.3816-3824.2005 PMID: 16127058; PubMed Central PMCID: PMC1195397.
27. Ritchie AV, Ushiro-Lumb I, Edemaga D, Joshi HA, De Ruiter A, Szumilin E, et al. SAMBA HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited settings. J Clin Microbiol. 2014;52(9):3377-83. doi: 10.1128/JCM.00593-14 PMID: 25031444.
28. Murtagh M, for UNITAID. HIV/AIDS Diagnostic Technology Landscape 2014, 4th Edition. http://unitaidorg/images/marketdynamics/publications/UNITAID-HIV-Diagnostic-Landscape-4th-editionpdf. 2014.
29. Rowley CF. Developments in CD4 and viral load monitoring in resource-limited settings. Clin Infect Dis. 2014;58(3):407-12. doi: 10.1093/cid/cit733 PMID: 24218101; PubMed Central PMCID: PMC3890339.
30. Scott L, Gous N, Carmona S, Stevens W. Laboratory evaluation of the Liat HIV Quant (IQuum) wholeblood and plasma HIV-1 viral load assays for point-of-care testing in South Africa. J Clin Microbiol. 2015;53(5):1616-21. doi: 10.1128/JCM.03325-14 PMID: 25740777; PubMed Central PMCID: PMC4400747.
31. Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr. 2013;64(1):74-8. Epub 2013/06/19. doi: 10. 1097/QAI.0b013e31829f05ac PMID: 23774877.
32. Johnston V, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. J Acquir Immune Defic Syndr. 2012;61(3):370-80. doi: 10.1097/QAI. 0b013e318266ee3f PMID: 22820803; PubMed Central PMCID: PMC3840925.
33. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009;49(12):1928-35. Epub 2009/11/17. PMID: 19911963; PubMed Central PMCID: PMC2789416.
34. Hoffmann CJ, Charalambous S, Grant AD, Morris L, Churchyard GJ, Chaisson RE. Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. TropMed Int Health. 2014;19(2):236-9. Epub 2014/03/04. PMID: 24588012; PubMed Central PMCID: PMC4070658.
35. Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, et al. High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy. Clin Infect Dis. 2014;58(7):1023-6. doi: 10.1093/cid/cit933 PMID: 24352348; PubMed Central PMCID: PMC3952602.
36. Llibre JM, Imaz A, Clotet B. From TMC114 to darunavir: five years of data on efficacy. AIDS Rev. 2013;15(2):112-21. PMID: 23708741.
37. Siliciano JD, Siliciano RF. Recent trends in HIV-1 drug resistance. Curr Opin Virol. 2013;3(5):487-94. doi: 10.1016/j.coviro.2013.08.007 PMID: 24021560; PubMed Central PMCID: PMC3963152.
38. Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, et al. Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 2012;67(4):995-1000. Epub 2012/01/20. doi: 10.1093/jac/dkr569 PMID: 22258921.
39. Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, et al. Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 2013;68(10):2339-43. Epub 2013/05/29. doi: 10.1093/jac/dkt199 PMID: 23711895; PubMed Central PMCID: PMC3772741.
40. Rosenbloom DI, Hill AL, Rabi SA, Siliciano RF, Nowak MA. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med. 2012;18(9):1378-85. doi: 10.1038/nm.2892 PMID: 22941277; PubMed Central PMCID: PMC3490032.
41. Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, et al. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014;59(6):888-96. doi: 10.1093/cid/ciu367 PMID: 24842909; PubMed Central PMCID: PMC4155445.
42. Fun A, Wensing AM, Verheyen J, Nijhuis M. Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012;9:63. Epub 2012/08/08. doi: 10.1186/1742-4690-9-63 PMID: 22867298; PubMed Central PMCID: PMC3422997.
43. Rabi SA, Laird GM, Durand CM, Laskey S, Shan L, Bailey JR, et al. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest. 2013;123(9):3848-60. Epub 2013/08/28. doi: 10.1172/JCI67399 PMID: 23979165.
44. World Health Organization HIV/AIDS Programme. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013.
45. Bronze M, Aitken SC, Wallis CL, Steegen K, Stuyver LJ, de Wit TF, et al. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol. J Virol Methods. 2013. Epub 2013/09/03. doi: 10.1016/j.jviromet.2013.08.015 PMID: 23994150.
46. Aitken SC, Bronze M, Wallis CL, Stuyver L, Steegen K, Balinda S, et al. A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only. J Clin Microbiol. 2013;51(6):1757-61. Epub 2013/03/29. doi: 10.1128/JCM.00118-13 PMID: 23536405; PubMed Central PMCID: PMC3716103.
47. Lapointe HR, Dong W, Lee GQ, Bangsberg DR, Martin JN, Mocello AR, et al. HIV Drug Resistance Testing by High-Multiplex "Wide" Sequencing on the MiSeq Instrument. Antimicrob Agents Chemother. 2015;59(11):6824-33. doi: 10.1128/AAC.01490-15 PMID: 26282425; PubMed Central PMCID: PMC4604392.
48. Chung MH, Beck IA, Dross S, Tapia K, Kiarie JN, Richardson BA, et al. Oligonucleotide Ligation Assay Detects HIV Drug Resistance Associated With Virologic Failure Among Antiretroviral-Naive Adults in Kenya. J Acquir Immune Defic Syndr. 2014;67(3):246-53. doi: 10.1097/QAI.0000000000000312 PMID: 25140907; PubMed Central PMCID: PMC4197120.
49. MacLeod I, Rowley CF, Essex M. Pan degenerate ampflification and adaptation for highly sensitive detection of ARV drug resistance [abstract 606]. Conference on Retroviruses and Opportunistic Infections. 2014.
50. Zhang G, Cai F, Zhou Z, Devos J, Wagar N, Diallo K, et al. Simultaneous Detection of Major Drug Resistance Mutations in the Protease and Reverse Transcriptase Genes for HIV-1 Subtype C Using a Multiplex Allele-specific (MAS) Assay. J Clin Microbiol. 2013. Epub 2013/08/30. doi: 10.1128/JCM. 01669-13 PMID: 23985909.
51. Clutter DS, Sánchez PR, Rhee SY, Shafer RW. Genetic Variability of HIV-1 for Drug Resistance Assay Development. PLoS One, under review. 2015.
52. Servais J, Lambert C, Fontaine E, Plesseria JM, Robert I, Arendt V, et al. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol. 2001;39(2):454-9. doi: 10. 1128/JCM.39.2.454-459.2001 PMID: 11158089; PubMed Central PMCID: PMC87758.
53. Vahey M, Nau ME, Barrick S, Cooley JD, Sawyer R, Sleeker AA, et al. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol. 1999;37(8):2533-7. PMID: 10405396; PubMed Central PMCID: PMC85275.
54. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646-55. doi: 10.1016/S0140-6736 (08) 61081-8 PMID: 18722869.
55. The H. I. V. Causal Collaboration. Boosted Lopinavir-Versus Boosted Atazanavir-Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clin Infect Dis. 2015. doi: 10.1093/cid/ciu1167 PMID: 25567330.
56. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr. 2007;44(4):417-22. doi: 10. 1097/QAI.0b013e31802e2940 PMID: 17159658.
57. Guiguet M, Ghosn J, Duvivier C, Meynard JL, Gras G, Partisani M, et al. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study. AIDS. 2012;26(18):2345-50. doi: 10. 1097/QAD.0b013e32835646e0 PMID: 22695301.
58. Castagna A, Spagnuolo V, Galli L, Vinci C, Nozza S, Carini E, et al. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results. AIDS. 2014;28(15):2269-79. doi: 10.1097/QAD.0000000000000407 PMID: 25058680.
59. Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;59(1):39-46. doi: 10.1097/QAI.0b013e31823df4da PMID: 22067667.
60. Barnhart M, Shelton JD. ARVs: The next generation. Going boldly together to new frontiers of HIV treatment. Global Health Science and Practice. 2015; http://www.ghspjournal.org/content/early/2015/01/28/GHSP-D-14-00243.full.pdf+html.